loadpatents
name:-0.83894300460815
name:-0.096508979797363
name:-0.32692098617554
Bianchi; Elisabetta Patent Filings

Bianchi; Elisabetta

Patent Applications and Registrations

Patent applications and USPTO patent grants for Bianchi; Elisabetta.The latest application filed is for "immunological signatures and parameters predicting therapeutic responses to anti-tnf therapy".

Company Profile
20.24.39
  • Bianchi; Elisabetta - Rome IT
  • BIANCHI; ELISABETTA - PARIS FR
  • BIANCHI; Elisabetta - Pomezia RM
  • Bianchi; Elisabetta - Pomezia IT
  • Bianchi; Elisabetta - Pommezia IT
  • Bianchi; Elisabetta - Via Sabotino IT
  • Bianchi; Elisabetta - Roma IT
*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.
Patent Activity
PatentDate
PCSK9 antagonist compounds
Grant 11,427,616 - Wood , et al. August 30, 2
2022-08-30
Immunological Signatures And Parameters Predicting Therapeutic Responses To Anti-tnf Therapy
App 20220128572 - ROGGE; LARS ;   et al.
2022-04-28
PCSK9 antagonists bicyclo-compounds
Grant 11,306,125 - Xiong , et al. April 19, 2
2022-04-19
Immunological signatures and parameters predicting therapeutic responses to anti-TNF therapy
Grant 11,249,090 - Rogge , et al. February 15, 2
2022-02-15
Modified Lipidated Relaxin B Chain Peptides And Their Therapeutic Use
App 20210292387 - DUCLOS; Olivier ;   et al.
2021-09-23
Cyclic Polypeptides For Pcsk9 Inhibition
App 20210284694 - Ricardo; Alonso ;   et al.
2021-09-16
Peptide Inhibitors Of Interleukin-23 Receptor And Their Use To Treat Inflammatory Diseases
App 20210261622 - Sun; Chengzao ;   et al.
2021-08-26
Pcsk9 Antagonists Bicyclo-compounds
App 20210214395 - Xiong; Yusheng ;   et al.
2021-07-15
Cyclic Polypeptides For Pcsk9 Inhibition
App 20210163538 - Ricardo; Alonso ;   et al.
2021-06-03
Modified lipidated Relaxin B chain peptides and their therapeutic use
Grant 10,988,523 - Brasseur , et al. April 27, 2
2021-04-27
Modified relaxin B chain peptides and their therapeutic use
Grant 10,988,524 - Illiano , et al. April 27, 2
2021-04-27
Modified lipidated Relaxin B chain peptides and their therapeutic use
Grant 10,961,295 - Duclos , et al. March 30, 2
2021-03-30
Long-acting Co-agonists Of The Glucagon And Glp-1 Receptors
App 20200392196 - Palani; Anandan ;   et al.
2020-12-17
Antibody Peptide Conjugates That Have Agonist Activity At Both The Glucagon And Glucagon-like Peptide 1 Receptors
App 20200392197 - Carrington; Paul E. ;   et al.
2020-12-17
Antibody peptide conjugates that have agonist activity at both the glucagon and glucagon-like peptide 1 receptors
Grant 10,800,826 - Carrington , et al. October 13, 2
2020-10-13
Long-acting co-agonists of the glucagon and GLP-1 receptors
Grant 10,793,615 - Palani , et al. October 6, 2
2020-10-06
Long-acting Co-agonists Of The Glucagon And Glp-1 Receptors
App 20200270325 - Palani; Anandan ;   et al.
2020-08-27
Pcsk9 Antagonist Compounds
App 20190389909 - Wood; Harold B. ;   et al.
2019-12-26
Co-agonists of the glucagon and GLP-1 receptors
Grant 10,493,125 - Palani , et al. De
2019-12-03
Long-acting Co-agonists Of The Glucagon And Glp-1 Receptors
App 20190338008 - Palani; Anandan ;   et al.
2019-11-07
Co-agonists of the glucagon and GLP-1 receptors
Grant 10,413,593 - Bianchi , et al. Sept
2019-09-17
Modified Lipidated Relaxin B Chain Peptides And Their Therapeutic Use
App 20190233494 - DUCLOS; Olivier ;   et al.
2019-08-01
Modified Lipidated Relaxin B Chain Peptides And Their Therapeutic Use
App 20190233493 - Brasseur; Denis ;   et al.
2019-08-01
Modified Relaxin B Chain Peptides And Their Therapeutic Use
App 20190233495 - ILLIANO; Stephane ;   et al.
2019-08-01
Insulin-incretin Conjugates
App 20190175744 - Palani; Anandan ;   et al.
2019-06-13
Antibody Peptide Conjugates That Have Agonist Activity At Both The Glucagon And Glucagon-like Peptide 1 Receptors
App 20190071483 - Carrington; Paul ;   et al.
2019-03-07
Co-agonists Of The Glucagon And Glp-1 Receptors
App 20180339017 - Palani; Anandan ;   et al.
2018-11-29
Immunological Signatures And Parameters Predicting Therapeutic Responses To Anti-tnf Therapy
App 20180267058 - ROGGE; LARS ;   et al.
2018-09-20
Co-agonists Of The Glucagon And Glp-1 Receptors
App 20170360893 - Bianchi; Elisabetta ;   et al.
2017-12-21
Oxyntomodulin analogs
Grant 9,593,155 - Carrington , et al. March 14, 2
2017-03-14
Co-agonists Of The Glucagon And Glp-1 Receptors
App 20160114000 - Bianchi; Elisabetta ;   et al.
2016-04-28
Oxyntomodulin Analogs
App 20150307580 - CARRINGTON; Paul E. ;   et al.
2015-10-29
Glucagon/GLP-1 receptor co-agonists
Grant 8,969,294 - Bianchi , et al. March 3, 2
2015-03-03
Cholesterol Derivatives Of Inhibitors Of Viral Fusion
App 20140094405 - PESSI; Antonello ;   et al.
2014-04-03
Cholesterol derivatives of inhibitors of viral fusion
Grant 8,629,101 - Pessi , et al. January 14, 2
2014-01-14
Glucagon/glp-1 Receptor Co-agonists
App 20130090286 - Bianchi; Elisabetta ;   et al.
2013-04-11
Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
Grant 8,268,779 - Sinha Roy , et al. September 18, 2
2012-09-18
Neuromedin U Receptor Agonists And Uses Thereof
App 20110301079 - Marsh; Donald J. ;   et al.
2011-12-08
Pharmaceutical Composition Comprising Oxyntomodulin Derivatives And A Method For Reducing Body Weight Using The Composition
App 20110183902 - Sinha Roy; Ranabir ;   et al.
2011-07-28
Pharmaceutical composition comprising oxyntomodulin derivatives and a method for reducing body weight using the composition
Grant 7,928,058 - Sinha Roy , et al. April 19, 2
2011-04-19
Apoa-1 Peptide Mimetics
App 20110046056 - Bianchi; Elisabetta ;   et al.
2011-02-24
Cholesterol Derivatives Of Inhibitors Of Viral Fusion
App 20100305028 - Pessi; Antonello ;   et al.
2010-12-02
Covalently stabilized chimeric coiled-coil HIV gp41 N-peptides with improved antiviral activity
Grant 7,811,577 - Bianchi , et al. October 12, 2
2010-10-12
Human antibodies interacting with HIV gp41
Grant 7,744,887 - Shiver , et al. June 29, 2
2010-06-29
Oxyntomodulin Derivatives
App 20100144617 - Sinha Roy; Ranabir ;   et al.
2010-06-10
Method for Shielding Functional Sites or Epitopes on Proteins
App 20100092505 - Bianchi; Elisabetta ;   et al.
2010-04-15
Neuromedin U Receptor Agonists And Uses Thereof
App 20100075907 - Marsh; Donald J. ;   et al.
2010-03-25
Method to Make a Peptide-Carrier Conjugate with a High Immunogenicity
App 20090104220 - Bianchi; Elisabetta ;   et al.
2009-04-23
Human Antibodies Interacting with Hiv Gp41
App 20070248613 - Shiver; John W. ;   et al.
2007-10-25
Neuromedin U receptor agonists and uses thereof
App 20070244048 - Marsh; Donald J. ;   et al.
2007-10-18
Stable Peptide Mimetic of Hiv Gp41 Fusion Intermediate
App 20070224212 - Bianchi; Elisabetta ;   et al.
2007-09-27
HCV NS3 protease inhibitors
Grant 6,995,177 - Bianchi , et al. February 7, 2
2006-02-07
Influenza virus vaccine
App 20040223976 - Bianchi, Elisabetta ;   et al.
2004-11-11
Vectors for dna delivery
App 20030207400 - Bianchi, Elisabetta ;   et al.
2003-11-06
Methodology to produce, and purify and assay polypeptides with the proteolytic activity of the HCV NS3 protease
Grant 6,197,536 - Steinkuhler , et al. March 6, 2
2001-03-06
Synthetic peptides useful as universal carriers for the preparation of immunogenic conjugates and their use in the development of synthetic vaccines
Grant 5,196,512 - Bianchi , et al. March 23, 1
1993-03-23

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.

© 2024 USPTO.report | Privacy Policy | Resources | RSS Feed of Trademarks | Trademark Filings Twitter Feed